DK1355641T3 - Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer - Google Patents

Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer

Info

Publication number
DK1355641T3
DK1355641T3 DK02719742T DK02719742T DK1355641T3 DK 1355641 T3 DK1355641 T3 DK 1355641T3 DK 02719742 T DK02719742 T DK 02719742T DK 02719742 T DK02719742 T DK 02719742T DK 1355641 T3 DK1355641 T3 DK 1355641T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
methanesulfonamide
ibuprofen
rejection reactions
Prior art date
Application number
DK02719742T
Other languages
Danish (da)
English (en)
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Application granted granted Critical
Publication of DK1355641T3 publication Critical patent/DK1355641T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK02719742T 2001-02-02 2002-01-30 Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer DK1355641T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (1)

Publication Number Publication Date
DK1355641T3 true DK1355641T3 (da) 2005-10-17

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719742T DK1355641T3 (da) 2001-02-02 2002-01-30 Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer

Country Status (26)

Country Link
US (1) US7560487B2 (https=)
EP (1) EP1355641B1 (https=)
JP (1) JP2004517948A (https=)
KR (1) KR100857898B1 (https=)
CN (1) CN1561205A (https=)
AT (1) ATE304846T1 (https=)
AU (1) AU2002250869B2 (https=)
BR (2) BR0206804A (https=)
CA (1) CA2432432C (https=)
CZ (1) CZ303665B6 (https=)
DE (1) DE60206245T2 (https=)
DK (1) DK1355641T3 (https=)
EE (1) EE05233B1 (https=)
ES (1) ES2248541T3 (https=)
HU (1) HU229070B1 (https=)
IL (1) IL157180A (https=)
IT (1) ITMI20010206A1 (https=)
MX (1) MXPA03006686A (https=)
NO (1) NO334285B1 (https=)
NZ (1) NZ526655A (https=)
PL (1) PL215109B1 (https=)
PT (1) PT1355641E (https=)
RU (1) RU2257895C2 (https=)
SK (1) SK287632B6 (https=)
WO (1) WO2002062330A2 (https=)
ZA (1) ZA200304861B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1579859E (pt) * 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
EP1883405A4 (en) 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
KR20150024919A (ko) * 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US20200003787A1 (en) * 2017-03-15 2020-01-02 Numares Ag Method for Using a Marker Set for Determining the Risk of Kidney Rejection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
RU2126262C1 (ru) * 1992-09-17 1999-02-20 Амген Боулдер Инк. Фармацевтическая композиция
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
EE200300340A (et) 2003-10-15
WO2002062330A2 (en) 2002-08-15
CA2432432A1 (en) 2002-08-15
DE60206245D1 (de) 2006-02-02
NO20033273D0 (no) 2003-07-18
RU2257895C2 (ru) 2005-08-10
NO20033273L (no) 2003-07-18
KR20030074725A (ko) 2003-09-19
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
KR100857898B1 (ko) 2008-09-10
ZA200304861B (en) 2004-06-30
CZ303665B6 (cs) 2013-02-20
MXPA03006686A (es) 2004-05-31
WO2002062330A3 (en) 2003-04-03
PT1355641E (pt) 2005-11-30
ES2248541T3 (es) 2006-03-16
AU2002250869B2 (en) 2006-10-19
ITMI20010206A1 (it) 2002-08-02
NZ526655A (en) 2005-02-25
HUP0303024A2 (hu) 2003-12-29
NO334285B1 (no) 2014-01-27
ATE304846T1 (de) 2005-10-15
EP1355641B1 (en) 2005-09-21
CA2432432C (en) 2008-03-25
DE60206245T2 (de) 2006-06-14
HUP0303024A3 (en) 2005-07-28
SK287632B6 (sk) 2011-04-05
PL215109B1 (pl) 2013-10-31
JP2004517948A (ja) 2004-06-17
EE05233B1 (et) 2009-12-15
PL363576A1 (en) 2004-11-29
CN1561205A (zh) 2005-01-05
RU2003126600A (ru) 2005-02-27
SK9732003A3 (en) 2003-11-04
BR0206804A (pt) 2004-02-03
EP1355641A2 (en) 2003-10-29
HU229070B1 (hu) 2013-07-29
IL157180A (en) 2009-06-15
CZ20032095A3 (en) 2004-05-12
US20040102520A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
DE60118604D1 (de) Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
DK3449934T3 (da) Behandling af glycogenlagringssygdom type II
SE9904176D0 (sv) New use
CO5271691A1 (es) Nuevos compuestos
ME01222B (me) Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
DK1336605T3 (da) Substituerede phenolderivater eller salte deraf som inhibitorer af koagulationsfaktor X
BR9909668A (pt) Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
DK1355641T3 (da) Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
PT1091747E (pt) Utilizacao de solucoes salinas isotermicas para a prevencao de inflamacoes
TR200003200T2 (tr) Faktör XA'yı önleyen heterosiklik türevler.
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
EA199700106A1 (ru) Замещенные 2-фенилпиридины в качестве гербицидов
BR0207434A (pt) Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE403644T1 (de) Amidinophenylbrenztraubensäure-derivat
WO2003039231A3 (en) Compounds and methods for treating transplant rejection
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
SHI et al. Experimental study on the pathological changes and early anastomosis of blood vessels in blast-wounded maxillofacial region in dog
LIU et al. Surgical management and its therapeutic effect of gunshot wounded femor al arteries immered in seawater in rabbits
MA26184A1 (fr) Rotor biologique immerge (r.b.i.) pour epuration des eaux usees
SE0202287D0 (sv) New compounds